Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves Pfizer Leukemia Drug

By Drug Discovery Trends Editor | September 4, 2012

The Food and Drug Administration has approved a new Pfizer drug to treat a rare form of blood and bone marrow cancer that causes a buildup of unhealthy white blood cells.

Pfizer’s Bosulif is a daily pill to treat chronic myeloid leukemia patients who carry a specific genetic variation. The disease is one of four types of the blood cancer, and accounts for about 15% of leukemia cases.

The disease, which usually affects seniors, causes the bone marrow to produce unhealthy white blood cells that do not grow and die like normal cells. Instead, the cells buildup in the bone marrow and crowd out healthy cells that are needed to fight off infections.

Bosulif works by blocking an enzyme called tyrosine kinase that triggers the production of unhealthy cells. The FDA approved the pill for patients with a genetic mutation, known as the Philadelphia chromosome, who do not respond to other cancer therapies, including Novartis’ Gleevec.

An estimated 5,430 patients will be diagnosed with chronic myelogenous leukemia this year, according to the FDA. The agency cleared the drug under its orphan drug program, which provides financial incentives for the development of drugs for rare diseases.

The FDA approved Bosulif based on a Pfizer study showing 34% of patients treated with the drug responded within the first six months of treatment. In patients previously treated with Gleevec, 33% had blood counts that returned to a normal range within 48 weeks. Fifty five percent of patients achieved normal blood counts with no evidence of leukemia within that same timeframe.

The most common side effects seen in patients included diarrhea, nausea, abdominal pain, rash, and fever.

Date: September 4, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50